fda glp-1 warning letters september 2025 news Issues 30 to Telehealth Firms Over Misleading Compounded Marketing FDA Issues Warnings Against Illegal

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA

To read more in detail (and explore the research further):

The primary endpoint was the percentage weight loss at six months (M6) compared to baseline

A public verdict index for longevity claims

It dissolves easily in waterand fits easily into your life.

SANTA CLARA, Feb 9 Pizza, pasta or Chinese take-out used to be the go-to Super Bowl spread for Marla Senzons family until the Florida retiree began taking a GLP1...